The somatomedins were originally recognized as GH dependent serum factors which mediated GH action on cartilage in-vitro, while the source of these serum factors was at first unknown, the liver was widely suspected. McConaghey and Sledge1 in 1970 reported that rat livers released somatomedins bioactivity during perfusion and the release was increased by GH. This finding has been confirmed with more specific assay methods and extended to studies of isolated hepatocytes2. Modern molecular biological probes have confirmed GH regulation of IGF-I gene expression in rat and mouse liver. The role of the liver as the major source of serum IGF-II is less well established in man because most of the studies of IGF-II gene expression have been done in rats and mice. In this species, IGF-II m RNA drops to a very low level in all tissues except choroid plexus and meninges3. The fact that IGF-II is not elevated in acromegaly and only decreases to about 50% of normal in hypopituitary patients is indicative of reduced GH dependence.


Choroid Plexus Longitudinal Bone Growth Fibrosarcoma Cell Line Hypopituitary Patient IGFI Action 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    P. McConaghey and C. G. Sledge. Production of sulphation factor by the perfused liver. Nature 225:1249 (1970).PubMedCrossRefGoogle Scholar
  2. 2.
    E. M. Spencer. Synthesis by cultured hepatocytes of somatomedin and its binding protein. Febs. Lett. 99:157 (1979).PubMedCrossRefGoogle Scholar
  3. 3.
    M. A. Hynes, P. J. Brooks, J. J. Van Wyk and P.K. Lund. Insulin-like growth factor II messenger ribonucleic acids are synthesized in the choroid plexus of the rat brain. Mol. Endo 2:47 (1988).CrossRefGoogle Scholar
  4. 4.
    A. J. D’Ercole, A. D. Stiles, and L. E. Underwood. Tissue concentrations of somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc. Natl. Acad. Sci. USA 81:935 (1984).PubMedCrossRefGoogle Scholar
  5. 5.
    L. J. Murphy, G. I. Bell, and H. G. Friesen. Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. Endocrinology 120:1279 (1987).PubMedCrossRefGoogle Scholar
  6. 6.
    W. H. Daughaday. A personal history of the origin of the somatomedin hypothesis and recent challenges to tis validity. Perspect. Biol. Med. (in press).Google Scholar
  7. 7.
    O. G. P. Isaksson, J.-O. Jansson, I. A. M. Gause. Growth hormone stiumates longitudinal bone growth directly. Science 216:1237 (1982).PubMedCrossRefGoogle Scholar
  8. 8.
    J. Isgaard, A. Nilsson, A. Lindahl, J.O. Jansson, and G. P. Isaksson. Effects of local administration of GH and IGF-I on longitudinal bone growth in rats. Am. J. Physiol. 250:E367 (1986).PubMedGoogle Scholar
  9. 9.
    N. L. Schlechter, S. M. Russell, E. M. Spencer, and C. S. Nicoll. Evidence suggesting that the direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin. Proc. Natl. Acad. Sci. USA 83:7932 (1986).PubMedCrossRefGoogle Scholar
  10. 10.
    A. D. Stiles, I. R. S. Sosenko, A. J. D’Ercole, and B. T. Smith. Relation of kidney tissue somatomedin C/insulin-like growth factor I to postnephrectomy renal growth in the rat. Endocrinology 117:2397 (1985).PubMedCrossRefGoogle Scholar
  11. 11.
    E. Jennische and H. A. Hansson. Regenerating skeletal muscle cells express insulin-like growth factor I. Acto Physiol Scand. 130:327 (1987).CrossRefGoogle Scholar
  12. 12.
    K. Megyesi, C. R. Kahn, J. Roth, and P. Gorden. Hypoglycemia in association with extrapancreatic tumors: Demonstration of elevated plasma NSILA-s by a new radioreceptor assay. J. Clin. Endocrinol. Metab. 38:931 (1974).PubMedCrossRefGoogle Scholar
  13. 13.
    W. H. Daughaday, B. Trivedi, and M. Kapadia. Measurement of insulin-like growth factor II by a specific radioreceptor assay in serum of normal individuals, patients with abnormal growth hormone secretion, and patients with tumor-associated hypoglycemia. J. Clin. Endocrinol. Metab. 53:289 (1981).PubMedCrossRefGoogle Scholar
  14. 14.
    T. Hyodo, K. Megyesi, C. R. Kahn, J. P. McLean, and H. G. Friesen, Adrenocortical carcinoma and hypoglycemia. Evidence for production of nonsuppressible insulin-like activity by the tumor. J. Clin. Endocrinol. Metab. 44:1175 (1977).PubMedCrossRefGoogle Scholar
  15. 15.
    U. Widmer, C. Schmid, E. R. Froesch. Effects of insulin-like growth factors on chick embryo hepatocytes. Acta Endocrinol. 108:237 (1985).PubMedGoogle Scholar
  16. 16.
    J. E. DeLarco and G. J. Todaro. A human fibrosarcoma cell line producing multiplication stimulating activity (MSA)-related peptides. Nature 272:356 (1978).CrossRefGoogle Scholar
  17. 17.
    Y. Nakanishi, J. L. Muishine, P. G. Kasprzyk, R. B. Natale, R. Maneckjee, I. Avis, A. M. Treston, A. F. Gazdar, J. D. Minna, and F. Cuttitta. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J. Clin. Invest. 82:354 (1988).PubMedCrossRefGoogle Scholar
  18. 18.
    W. H. Daughaday, M. A. Emanuele, M. H. Brooks, A. L. Barbato, M. Kapadia, and P. Rotwein. Insulin-like growth factor II synthesis and secretion by a leiomyosarcoma with associated hypoglycemia. N. Engl. J. Med. 319:1434 (1988).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • William H. Daughaday
    • 1
  1. 1.Department of MedicineWashington University School of MedicineSt. LouisUSA

Personalised recommendations